Angus J. Grant, PhD, was appointed Executive Vice President of Business Development at Teva in August 2023. In this role, Angus leads the company’s business development, licensing and alliance management functions to accelerate Teva’s momentum bringing innovative therapies and impactful medicines to patients worldwide through strategic partnerships and collaborations across the academic, healthcare and technology sectors.

Angus brings more than 25 years of experience across multiple key functions in the pharmaceutical and biotech industry, including business development, corporate strategy, mergers and acquisitions (M&A), investing, research and development, and regulatory affairs. Throughout his career, Angus has overseen the end-to-end process for corporate strategy and partnerships, driving external innovation, fostering collaborations, and attracting investments with patient-centric vision and unwavering commitment to transformational science.

Prior to Teva, Angus held several executive leadership positions at BeiGene, a global, commercial-stage biotechnology company, where he led corporate strategy and operations. In 2006, Angus joined pharmaceutical manufacturer, Celgene, and held various leadership positions over his 12-year career with the company. Angus launched his Celgene career as Vice President of North American Regulatory, and then moved to the UK in 2008 to support the integration of Pharmion and to build out the European regulatory function. In 2011, Angus returned to the US as Corporate Vice President of Business Development to build alliance management while brokering and executing business agreements to support company growth. Angus orchestrated business deals ranging from R&D and commercialization collaborations to early equity investments, supply collaborations, global and regional licensing agreements, and M&A, including the $9 billion Juno acquisition in 2018.

Angus left Celgene in 2018 to serve as CEO of the Dementia Discovery Fund (DDF), inspired by their mission to invest in early-stage biotech companies most likely to develop transformative treatments for neurodegenerative diseases that have long lacked effective treatments. He served as CEO of the DDF until 2020, compelled by a personal commitment to try and help the millions of people suffering from one of the most significant health crises of the 21st century.

Earlier in his career, Angus worked in business development and regulatory roles at Novartis Oncology, Merck KGaA, Rhone Poulanc-Rohrer, and SmithKline Beecham.

Angus earned his undergraduate degree in biology from the University of Richmond and his PhD in anatomy and immunology from the Medical College of Virginia. He completed his postdoctoral training at the National Cancer Institute and then served as a Senior Staff Fellow in the Division of Cell and Gene Therapies at the US Food and Drug Administration before entering the pharmaceutical industry. He is a published scientist, co-authoring more than 15 articles in peer-reviewed scientific journals. Angus currently serves as Chair of the Board for Toronto Innovation and Acceleration Partners.